Source:http://linkedlifedata.com/resource/pubmed/id/20376076
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2011-2-10
|
| pubmed:abstractText |
We sought to determine whether the antihypertensive drug nebivolol has beneficial effects on vascular markers of inflammation and oxidation in obese African-American patients with hypertension when exposed to exercise-induced stress. Forty-three obese, African-American subjects with hypertension were treated with nebivolol (5-10?mg/day) for 8 weeks. Before treatment the subjects underwent an exercise treadmill study to a level of eight metabolic equivalents. Circulating levels of soluble interleukin-6 (sIL-6), vascular cell adhesion molecule (VCAM-1), adiponectin and leptin were measured at pre-treadmill, and 1?min, 30?min, 60?min and 24?h after treadmill. After the 8-week treatment period, exercise treadmill study and the measurement of markers were repeated. Treatment with nebivolol reduced levels of sVCAM-1 at pre-exercise by 21% and at 1 and 30?min by 12.5 and 20%, respectively (P<0.005 from corresponding time point). In nebivolol-treated patients there was a reduction in sIL-6 levels by 20% and pre-exercise and at 1 and 60?min by 19.7 and 33.5%, respectively (P<0.005 from corresponding time point). Treatment with nebivolol increased levels of serum adiponectin by 28% (P=0.012) and decreased levels of leptin by 32% (P<0.005 from pre-treatment). Treatment with nebivolol improves markers of inflammation and obesity in a high-risk African-American population. Moreover, this effect is potentiated in response to exercise-induced stress. These results suggest that nebivolol differentially regulates markers of inflammation and obesity, thereby providing vascular protection.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adiponectin,
http://linkedlifedata.com/resource/pubmed/chemical/Antihypertensive Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Benzopyrans,
http://linkedlifedata.com/resource/pubmed/chemical/Biological Markers,
http://linkedlifedata.com/resource/pubmed/chemical/Blood Glucose,
http://linkedlifedata.com/resource/pubmed/chemical/Cholesterol, HDL,
http://linkedlifedata.com/resource/pubmed/chemical/Cholesterol, LDL,
http://linkedlifedata.com/resource/pubmed/chemical/Ethanolamines,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-6,
http://linkedlifedata.com/resource/pubmed/chemical/Leptin,
http://linkedlifedata.com/resource/pubmed/chemical/Lipids,
http://linkedlifedata.com/resource/pubmed/chemical/Vascular Cell Adhesion Molecule-1,
http://linkedlifedata.com/resource/pubmed/chemical/nebivolol
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
1476-5527
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
25
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
196-202
|
| pubmed:meshHeading |
pubmed-meshheading:20376076-Adiponectin,
pubmed-meshheading:20376076-African Americans,
pubmed-meshheading:20376076-Antihypertensive Agents,
pubmed-meshheading:20376076-Benzopyrans,
pubmed-meshheading:20376076-Biological Markers,
pubmed-meshheading:20376076-Blood Glucose,
pubmed-meshheading:20376076-Cholesterol, HDL,
pubmed-meshheading:20376076-Cholesterol, LDL,
pubmed-meshheading:20376076-Ethanolamines,
pubmed-meshheading:20376076-Exercise,
pubmed-meshheading:20376076-Female,
pubmed-meshheading:20376076-Humans,
pubmed-meshheading:20376076-Hypertension,
pubmed-meshheading:20376076-Inflammation,
pubmed-meshheading:20376076-Interleukin-6,
pubmed-meshheading:20376076-Leptin,
pubmed-meshheading:20376076-Lipids,
pubmed-meshheading:20376076-Male,
pubmed-meshheading:20376076-Middle Aged,
pubmed-meshheading:20376076-Obesity,
pubmed-meshheading:20376076-Stress, Physiological,
pubmed-meshheading:20376076-Treatment Outcome,
pubmed-meshheading:20376076-Vascular Cell Adhesion Molecule-1
|
| pubmed:year |
2011
|
| pubmed:articleTitle |
Effects of nebivolol in obese African Americans with hypertension (NOAAH): markers of inflammation and obesity in response to exercise-induced stress.
|
| pubmed:affiliation |
Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA.
|
| pubmed:publicationType |
Journal Article,
Controlled Clinical Trial,
Research Support, N.I.H., Extramural
|